Natco Pharma (BOM:524816) Cyclically Adjusted Revenue per Share: ₹184.76 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524816 Natco Pharma Ltd BOM:524816
82 GF Score
Price ₹853.35
GF Value ₹824.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma Cyclically Adjusted Revenue per Share?

Natco Pharma BOM:524816 -0.57% 82 Cyclically Adjusted Revenue per Share is ₹184.76 as of Jun. 2026. GuruFocus rates BOM:524816 with a GF Score™ of 82/100 and a GF Value™ of ₹824.08 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Natco Pharma's adjusted revenue per share for the three months ended in Jun. 2026 was ₹41.050. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹184.76 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Natco Pharma's average Cyclically Adjusted Revenue Growth Rate was 9.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Natco Pharma was 14.70% per year. The lowest was 8.70% per year. And the median was 13.35% per year.

As of today (2026-08-30), Natco Pharma's current stock price is ₹853.35. Natco Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹184.76. Natco Pharma's Cyclically Adjusted PS Ratio of today is 4.62.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Natco Pharma was 11.48. The lowest was 4.50. And the median was 6.43.


Natco Pharma  (BOM:524816) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Natco Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=853.35/184.76
=4.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Natco Pharma was 11.48. The lowest was 4.50. And the median was 6.43.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Natco Pharma Cyclically Adjusted Revenue per Share Related Terms


Natco Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Natco Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma Cyclically Adjusted Revenue per Share Chart

Natco Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.78 120.64 140.33 161.16 180.22

Natco Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.75 176.70 178.88 180.22 184.76

BOM:524816 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Cyclically Adjusted PS Ratio falls into.


BOM:524816
82GF Score
Natco Pharma Ltd BOM:524816
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natco Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Natco Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=41.05/167.3573*167.3573
=41.050

Current CPI (Jun. 2026) = 167.3573.

Natco Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 26.164 105.961 41.324
201612 38.319 105.196 60.962
201703 32.246 105.196 51.300
201706 25.413 107.109 39.708
201709 24.253 109.021 37.230
201712 31.664 109.404 48.437
201803 41.501 109.786 63.264
201806 29.125 111.317 43.788
201809 29.364 115.142 42.680
201812 30.271 115.142 43.999
201903 23.147 118.202 32.773
201906 26.987 120.880 37.363
201909 26.652 123.175 36.212
201912 26.440 126.235 35.053
202003 23.394 124.705 31.395
202006 30.877 127.000 40.689
202009 43.954 130.118 56.534
202012 19.431 130.889 24.845
202103 -1.673 131.771 -2.125
202106 22.484 134.084 28.063
202109 20.685 135.847 25.483
202112 30.674 138.161 37.156
202203 30.542 138.822 36.820
202206 48.454 142.347 56.967
202209 23.659 144.661 27.371
202212 26.957 145.763 30.951
202303 48.598 146.865 55.379
202306 63.117 150.280 70.289
202309 57.580 151.492 63.610
202312 42.370 152.924 46.369
202403 58.538 153.035 64.017
202406 76.069 155.789 81.718
202409 76.541 157.882 81.135
202412 26.525 158.323 28.039
202503 68.167 157.552 72.410
202506 74.200 159.755 77.731
202509 76.090 162.289 78.466
202512 36.146 163.281 37.048
202603 41.273 164.272 42.048
202606 41.050 167.357 41.050

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹184.76 mean?
Natco Pharma (BOM:524816) has a Cyclically Adjusted Revenue per Share of ₹184.76 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Natco Pharma and its competitors.
Is Natco Pharma's Cyclically Adjusted Revenue per Share too high?
Natco Pharma's current Cyclically Adjusted Revenue per Share is ₹184.76. Overall, Natco Pharma has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Natco Pharma's Cyclically Adjusted Revenue per Share of ₹184.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Natco Pharma and its competitors. Natco Pharma's current Cyclically Adjusted Revenue per Share is ₹184.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (BOM:524816) is currently considered Fairly Valued. The stock's GF Value™ is ₹824.08, compared to a current price of ₹853.35 — trading 3.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹184.76. Natco Pharma's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Natco Pharma (BOM:524816), the current Cyclically Adjusted Revenue per Share is ₹184.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (BOM:524816) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be overvalued. The current stock price of ₹853.35 is trading 3.6% above its estimated GF Value™ of ₹824.08. GuruFocus considers Natco Pharma to be Fairly Valued.

Key valuation signals for BOM:524816:

  • Cyclically Adjusted Revenue per Share: ₹184.76
  • GF Value™: ₹824.08 vs. price of ₹853.35 (3.6% above fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the BOM:524816 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Natco Pharma Business Description

Other Exchanges NATCOPHARM:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
82GF Score

Get the complete analysis for BOM:524816

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹853.35
Price
₹824.08
GF Value